Profile data is unavailable for this security.
About the company
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
- Revenue in USD (TTM)90.17m
- Net income in USD-175.84m
- Incorporated1998
- Employees137.00
- LocationNektar Therapeutics455 Mission Bay Boulevard SouthSAN FRANCISCO 94158United StatesUSA
- Phone+1 (415) 482-5300
- Fax+1 (415) 339-5300
- Websitehttps://www.nektar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences Inc | 33.40m | -115.26m | 306.18m | 158.00 | -- | 0.8919 | -- | 9.17 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 307.41m | 75.00 | -- | 0.5485 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 309.29m | 335.00 | -- | 3.65 | -- | 3.75 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 310.93m | 122.00 | -- | 2.97 | -- | 433.61 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 315.43m | 534.00 | -- | -- | -- | 1.33 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| AC Immune SA | 16.28m | -59.67m | 315.45m | 133.00 | -- | 1.78 | -- | 19.37 | -0.7061 | -0.7061 | 0.1918 | 1.78 | 0.0803 | -- | 1.92 | 122,440.00 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 318.93m | 203.00 | -- | 0.5863 | -- | 1.80 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 322.26m | 137.00 | -- | 2.54 | -- | 3.57 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Sutro Biopharma Inc | 154.07m | -114.96m | 328.00m | 300.00 | -- | 2.55 | -- | 2.13 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 333.46m | 74.00 | -- | 1.09 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 334.05m | 123.00 | -- | 11.94 | -- | 8.72 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 335.24m | 67.00 | -- | 1.74 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Fractyl Health Inc | 148.00k | -83.16m | 338.02m | 102.00 | -- | 4.02 | -- | 2,283.92 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -37.50m | 338.16m | 11.00 | -- | 4.29 | -- | -- | -4.50 | -4.50 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -75.43 | -232.67 | -101.00 | -- | -- | -- | -- | -- | -- | -46.11 | 0.0552 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Erasca Inc | 0.00 | -126.86m | 341.52m | 126.00 | -- | 1.03 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to Nektar Therapeutics's reporting currency: US Dollar USD
37.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 10 May 2024 | 18.34m | 9.99% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.98m | 6.53% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 7.57m | 4.12% |
| PRIMECAP Management Co.as of 31 Mar 2024 | 6.97m | 3.79% |
| Monaco Asset Management SAMas of 31 Mar 2024 | 5.83m | 3.18% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 4.62m | 2.52% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.13m | 2.25% |
| Stonepine Capital Management LLCas of 31 Mar 2024 | 3.48m | 1.90% |
| Citadel Advisors LLCas of 31 Mar 2024 | 3.19m | 1.74% |
| Millennium Management LLCas of 31 Mar 2024 | 2.98m | 1.63% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
